Baxter International Inc. [NYSE: BAX] stock went on a downward path that fall over -3.43% on Thursday, amounting to a one-week price decrease of less than -1.09%. The company report on September 23, 2020 that Baxter Announces U.S. FDA Approval of Clinimix and Clinimix E with Higher Protein for Patients Requiring Parenteral Nutrition.
New formulations provide up to 60% more protein (amino acid) than current Clinimix formulations while delivering less dextrose1 .
Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, today announced the U.S. Food and Drug Administration (FDA) approval of new formulations of Clinimix (amino acids in dextrose) Injections and Clinimix E (amino acids with electrolytes in dextrose and calcium) Injections. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.,2 making it easier to reach patient protein targets while delivering less fluid and dextrose than provided by existing formulations.3,4.
Over the last 12 months, BAX stock dropped by -9.26%. The one-year Baxter International Inc. stock forecast points to a potential upside of 18.08. The average equity rating for BAX stock is currently 1.90, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $40.37 billion, with 509.00 million shares outstanding and 505.52 million shares in the current float. Compared to the average trading volume of 2.99M shares, BAX stock reached a trading volume of 4321886 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Baxter International Inc. [BAX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BAX shares is $96.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BAX stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Baxter International Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 01, 2020. The new note on the price target was released on September 04, 2020, representing the official price target for Baxter International Inc. stock. Previously, the target price had yet another raise to $100, while Oppenheimer analysts kept a Outperform rating on BAX stock. On March 19, 2020, analysts increased their price target for BAX shares from 87 to 95.
The Average True Range (ATR) for Baxter International Inc. is set at 1.98, with the Price to Sales ratio for BAX stock in the period of the last 12 months amounting to 3.54. The Price to Book ratio for the last quarter was 4.94, with the Price to Cash per share for the same quarter was set at 7.98. Price to Free Cash Flow for BAX in the course of the last twelve months was 39.69 with Quick ratio for the last quarter at 2.30.
BAX Stock Performance Analysis:
Baxter International Inc. [BAX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.09. With this latest performance, BAX shares dropped by -4.84% in over the last four-week period, additionally sinking by -9.25% over the last 6 months – not to mention a drop of -9.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BAX stock in for the last two-week period is set at 42.56, with the RSI for the last a single of trading hit 41.18, and the three-weeks RSI is set at 42.69 for Baxter International Inc. [BAX]. The present Moving Average for the last 50 days of trading for this stock 82.36, while it was recorded at 80.07 for the last single week of trading, and 85.61 for the last 200 days.
Insight into Baxter International Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Baxter International Inc. [BAX] shares currently have an operating margin of +16.79 and a Gross Margin at +43.01. Baxter International Inc.’s Net Margin is presently recorded at +8.81.
Return on Total Capital for BAX is now 15.16, given the latest momentum, and Return on Invested Capital for the company is 8.18. Return on Equity for this stock inclined to 12.77, with Return on Assets sitting at 5.92. When it comes to the capital structure of this company, Baxter International Inc. [BAX] has a Total Debt to Total Equity ratio set at 75.63. Additionally, BAX Total Debt to Total Capital is recorded at 43.06, with Total Debt to Total Assets ending up at 32.77. Long-Term Debt to Equity for the company is recorded at 67.48, with the Long-Term Debt to Total Capital now at 38.42.
Reflecting on the efficiency of the workforce at the company, Baxter International Inc. [BAX] managed to generate an average of $20,020 per employee. Receivables Turnover for the company is 6.13 with a Total Asset Turnover recorded at a value of 0.67.Baxter International Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.30 and a Current Ratio set at 3.00.
BAX Stock EPS
With the latest financial reports released by the company, Baxter International Inc. posted 0.74/share EPS, while the average EPS was predicted by analysts to be reported at 0.84/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Baxter International Inc. go to 10.00%.
Baxter International Inc. [BAX] Insider Position Details
There are presently around $34,269 million, or 88.70% of BAX stock, in the hands of institutional investors. The top three institutional holders of BAX stocks are: BLACKROCK INC. with ownership of 44,569,176, which is approximately 7.949% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 39,980,621 shares of the stock with an approximate value of $3.15 billion in BAX stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $2.27 billion in BAX stock with ownership of nearly -3.584% of the company’s market capitalization.
Positions in Baxter International Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 470 institutional holders increased their position in Baxter International Inc. [NYSE:BAX] by around 35,798,218 shares. Additionally, 481 investors decreased positions by around 33,925,143 shares, while 241 investors held positions by with 364,882,860 shares. The mentioned changes placed institutional holdings at 434,606,221 shares, according to the latest SEC report filing. BAX stock had 95 new institutional investments in for a total of 7,641,151 shares, while 66 institutional investors sold positions of 3,449,775 shares during the same period.